BioInvent International AB

9:15 AM - 9:30 AM (JST), Wednesday, March 6, 2019 ・ 2nd Floor
BioInvent International AB (OMXS: BINV), is focused on the discovery and development of novel and first-in-class and best-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program BI-1206 is currently in Phase l/lla for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells of the tumor microenvironment relevant to solid and hematologic cancers, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance.

The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials.
Ticker:
BINV
Exchange:
NASDAQ OMX Stockholm
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Sweden
Year Founded:
1997
Main Therapeutic Focus:
Lead Product in Development:
BI-1206
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5